OrbiMed’s BioXcel Therapeutics BTAI Stock Holding History

OrbiMed’s Portfolio BTAI Stock Details BTAI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-6,706	Closed	-$2.4M	–	142
2020 Q1	$2.4M	Buy	+6,706	New	+$2.41M	0.04%	125

Other funds holding BTAI

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AIM

Artemis Investment Management Edinburgh, United Kingdom $11.2B AUM 80.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

ACP

Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

OrbiMed's BTAI Position: Q2 2020 in Review

OrbiMed sold out of BioXcel Therapeutics (BTAI) in Q2 2020, closing a stake of 6,706 shares — an estimated $2.4M sold.

OrbiMed first reported a position in BTAI in Q1 2020 and held it in 1 quarter. The position peaked at $2.4M in Q1 2020. 104 funds tracked by Wall St. Rank hold BTAI as of Q2 2020.

OrbiMed reported no remaining BioXcel Therapeutics position as of Q2 2020 after selling out during the quarter.
OrbiMed sold 6,706 BioXcel Therapeutics shares in Q2 2020, an estimated $2.4M.
OrbiMed first reported a position in BioXcel Therapeutics in Q1 2020 and held it in 1 quarter.
OrbiMed's BioXcel Therapeutics position peaked at $2.4M in Q1 2020.
104 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q2 2020.

Based on OrbiMed's 13F filing for Q2 2020, filed 14 Aug 2020.